A number of investment brokers have recently updated their price targets on shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/06/2016 – BioCryst Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 10 price target on the stock.

02/24/2016 – Noble Financial began new coverage on BioCryst Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 8 price target on the stock.

02/09/2016 – BioCryst Pharmaceuticals, Inc. had its “perform” rating reiterated by analysts at Oppenheimer.

02/09/2016 – BioCryst Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Rodman & Renshaw. They now have a USD 10 price target on the stock.

02/09/2016 – BioCryst Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 5 price target on the stock.

02/09/2016 – BioCryst Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 6 price target on the stock.

02/09/2016 – BioCryst Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Jefferies. They now have a USD 2 price target on the stock.

02/08/2016 – BioCryst Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Needham & Company.

02/08/2016 – BioCryst Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at Piper Jaffray. They now have a USD 5 price target on the stock.

11/11/2015 – BioCryst Pharmaceuticals, Inc. was downgraded to “underperform” by analysts at Bank of America Merrill Lynch. They now have a USD 10 price target on the stock.

08/10/2015 – BioCryst Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 15 price target on the stock.

05/12/2015 – BioCryst Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 12 price target on the stock.

01/28/2015 – BioCryst Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 20 price target on the stock.

06/23/2014 – BioCryst Pharmaceuticals, Inc. was upgraded to “outperform” by analysts at Wells Fargo. They now have a USD 17 price target on the stock.

05/30/2014 – BioCryst Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at ING. They now have a USD 24 price target on the stock.

The share price of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was up +4.03% during the last day of trading, with a day high of 2.87. 880391 shares were traded during the last session.

The stock’s 50 day moving average is 2.99 and its 200 day moving average is 6.20. The stock’s market capitalization is 208.27M. BioCryst Pharmaceuticals, Inc. has a 52-week low of 1.63 and a 52-week high of 16.83.

View other investors thoughts on BioCryst Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.